Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
1.190
0.00 (0.00%)
At close: Dec 20, 2024, 4:00 PM
1.230
+0.040 (3.37%)
After-hours: Dec 20, 2024, 7:11 PM EST
Atai Life Sciences Revenue
Atai Life Sciences had revenue of $40.00K in the quarter ending September 30, 2024, a decrease of -54.02%. This brings the company's revenue in the last twelve months to $331.00K, down -0.90% year-over-year. In the year 2023, Atai Life Sciences had annual revenue of $314.00K with 34.76% growth.
Revenue (ttm)
$331.00K
Revenue Growth
-0.90%
P/S Ratio
n/a
Revenue / Employee
$3,988
Employees
83
Market Cap
199.68M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 314.00K | 81.00K | 34.76% |
Dec 31, 2022 | 233.00K | -20.14M | -98.86% |
Dec 31, 2021 | 20.38M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Inogen | 331.52M |
MacroGenics | 141.33M |
ADC Therapeutics | 70.72M |
Biodesix | 65.56M |
SOPHiA GENETICS | 64.49M |
Verastem | 10.00M |
Akso Health Group | 2.41M |
Inhibrx Biosciences | 1.57M |
ATAI News
- 2 months ago - IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG - GlobeNewsWire
- 3 months ago - atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Psychedelic Stock Deep Dive: Atai Life Sciences - Seeking Alpha
- 4 months ago - atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 months ago - Psychedelic drug contender stocks drop after FDA rejects MDMA treatment - Market Watch
- 4 months ago - atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference - GlobeNewsWire
- 6 months ago - atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference - GlobeNewsWire
- 6 months ago - atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a - GlobeNewsWire